---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-23-305187"
form_type: "8-K"
ticker: "TCRT"
cik: "0001107421"
company_name: "Alaunos Therapeutics, Inc."
filed_at: "2023-12-28T23:59:59+00:00"
generated_at: "2026-06-07T06:13:43.712773+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Alaunos Therapeutics terminates CEO Kevin S. Boyle; separation payment ~$331,990 plus consulting deal

## Summary
- CEO Kevin S. Boyle terminated effective Dec 22, 2023; separation payment ~$331,990 (six months base salary + COBRA).
- Mr. Boyle also executed a mutual release and resigned from board of directors.
- Consulting agreement from Jan 1, 2024, for six months at $15,000/month for strategic advisory.
- No successor or interim CEO announced; transition details limited.

## SEC filing metadata
- accession: 0001193125-23-305187
- form_type: 8-K
- ticker: TCRT
- cik: 0001107421
- company_name: Alaunos Therapeutics, Inc.
- filed_at: 2023-12-28T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1107421/000119312523305187/0001193125-23-305187-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1107421/000119312523305187/d473634d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-23-305187
- JSON: https://secwatch.observer/filing/0001193125-23-305187.json
- Plain text: https://secwatch.observer/filing/0001193125-23-305187.txt

## Key facts
- Executive change
  Kevin S. Boyle, Sr. resigned as Director at Alaunos Therapeutics, Inc..
  - Action: resigned
  - Role: Director
  source text: Pursuant to the terms of his employment agreement, upon his termination Mr. Boyle was deemed to automatically resign from the Company’s board of directors.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312523305187/0001193125-23-305187-index.htm
- Executive change
  Kevin S. Boyle, Sr. was terminated as Chief Executive Officer at Alaunos Therapeutics, Inc..
  - Action: terminated
  - Role: Chief Executive Officer
  source text: On December 22, 2023, Alaunos Therapeutics, Inc. (the “Company”) entered into a Separation and Release Agreement, effective December 22, 2023, with Kevin S. Boyle, Sr. (the “Separation Agreement”), the Company’s Chief Executive Officer, in connection with Mr. Boyle’s termination.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1107421/000119312523305187/0001193125-23-305187-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.